Preloader

FOCUS CGP
Comprehensive Genomic Profiling

Journey toward personalized treatment with a comprehensive genetic mapping of the tumor.

The Future of Precision Oncology Is Now in Türkiye with Foundation Medicine Technology

FOCUS CGP is a comprehensive solid tumor panel developed using Foundation Medicine technology.

Technical Specifications
Method: NGS – Hybrid CaptureCoverage: ~2000x (High Sensitivity)

Coverage: 335 Genes (>2 Mb)*

321 Genes: All exons

22 Genes: Exons + selected intronic regions

12 Genes: Critical fusion partner introns

*Designed to be equivalent in scope to the FoundationOne® CDX test panel.

Sample Requirements:

FFPE (Paraffin Block) or

Surgical Resection / Fine Needle Aspiration (FNA) / Cell Block

Genomic Signatures: TMB, gLOH, MSI, HRDsig (Across all cancer types)
Assay Kit:  ROCHE AVENIO CGP v2 (CE-IVD approved)Sequencing System: İlumina NextSeq 550 DX (CE-IVD approved)
Bioinformatics System: Foundation Medicine (FMI)Accreditation: This test is CAP Accredited.

Other Features:

  • Enables genomic profiling of Cancers of Unknown Primary (CUP).
  • Detects novel gene fusions and intronic breakpoints.
  • Provides an HRDsig score across all solid tumors, independent of BRCA mutation status.
  • Classifies MSI into three categories—MSI-Stable, MSI-High, and MSI-Equivocal—providing greater accuracy and confidence in immunotherapy decision-making.
  • Delivers high-sensitivity DNA-based detection of clinically relevant alterations involving ALK, ROS1, RET, NTRK, and MET, without requiring RNA analysis.
 
  

*Single biomarkers analyzed by IHC and FISH methods can also be integrated into the report as needed.Roche_Logo

FOCUS CGP - Comprehensive Genomic ProfilingFOCUS CGP - Comprehensive Genomic Profiling

//
Our customer support team is here to answer your questions!